RELAPSING AQP4 ANTIBODY NEGATIVE NMO WITH MOG ANTIBODIES

RELAPSING AQP4 ANTIBODY NEGATIVE NMO WITH MOG ANTIBODIES

Dades bibliogràfiques
Autors principals:	Elsone, L, Waters, P, Woodhall, M, Mutch, K, Jacob, A
Format:	Conference item
Publicat:	2014

Ítems similars

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
per: Sato, D, et al.
Publicat: (2014)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
per: Kezuka, T, et al.
Publicat: (2014)

Glycine receptor antibody — a marker for NMO/ NON-MS demyelination?
per: Hamid, S, et al.
Publicat: (2015)

Distinguishing the brain MRI features of MS, AQP4-and MOG-antibody disease.
per: Jurynczyk, M, et al.
Publicat: (2016)

MOG-IGG IN NMO AND NMO-LIKE DISORDERS
per: Luppe, S, et al.
Publicat: (2014)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
per: Jurynczyk, M, et al.
Publicat: (2017)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease
per: Jurynczyk, M, et al.
Publicat: (2017)

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
per: Juryńczyk, M, et al.
Publicat: (2016)

Predictors of relapse in MOG antibody associated disease: a cohort study
per: Saif Huda, et al.
Publicat: (2021-11-01)

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
per: Yeo, T, et al.
Publicat: (2019)

Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
per: Waters, P, et al.
Publicat: (2015)

Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies
per: Yeo, T, et al.
Publicat: (2020)

Recurrent optic neuritis associated with MOG antibody seropositivity
per: Chang, T, et al.
Publicat: (2017)

Seronegative NMO: a sensitive AQP4 antibody test clarifies clinical features and next challenges.
per: Fujihara, K, et al.
Publicat: (2013)

MOG antibody-associated disease – a new entity or one of the forms of the NMO spectrum?
per: Dominika Czarnecka, et al.
Publicat: (2019-10-01)

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes
per: Juryńczyk, M, et al.
Publicat: (2015)

International multicenter examination of MOG antibody assays
per: Reindl, M, et al.
Publicat: (2020)

NMO-IgG/Aqp4-Ab belongs to the IgG1 subclass and activates complement in vitro
per: Jarius, S, et al.
Publicat: (2007)

Features of the diagnosis and treatment of patients with AQP-4-positive neuromyelitis optica and MOG antibody disease
per: V. E. Avdeeva, et al.
Publicat: (2021-11-01)

Prevalence of serum MOG antibody and AQP4 antibody in optic neuritis after SARS-CoV-2 infection
per: Chuan-bin Sun
Publicat: (2023-11-01)

A Longitudinal Comparison of the Recovery Patterns of Optic Neuritis with MOG Antibody-Seropositive and AQP4 Antibody-Seropositive or -Seronegative for Both Antibodies
per: Lin Zhou, et al.
Publicat: (2022-01-01)

Case report: Satralizumab as an adjunctive therapy for AQP-4 antibody and MOG antibody dual-negative optic neuritis in a third-trimester pregnancy case
per: Chuanbin Sun, et al.
Publicat: (2024-12-01)

Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis
per: Sotaro Mori, et al.
Publicat: (2020-01-01)

A novel sensitive assay for aqueporin-4 antibodies (NMO-IgG)
per: Waters, P, et al.
Publicat: (2007)

An international multicentre validation experiment for MOG antibodies
per: Reindl, M, et al.
Publicat: (2018)

A 41-year-old woman with acute weakness and encephalopathy associated with MOG antibodies.
per: Morris, K, et al.
Publicat: (2015)

Disease course and disability outcomes in MOG-antibody disease in the UK
per: Jurynczyk, M, et al.
Publicat: (2017)

Different immunological mechanisms between AQP4 antibody-positive and MOG antibody-positive optic neuritis based on RNA sequencing analysis of whole blood
per: Xuelian Chen, et al.
Publicat: (2023-03-01)

Clinical presentation and prognosis in MOG-antibody disease: a UK study
per: Jurynczyk, M, et al.
Publicat: (2017)

Clinical spectrum associated with aquaporin-4 antibodies (NMO-IgG)
per: Y. Blanco, et al.
Publicat: (2010-01-01)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
per: Luca Bollo, et al.
Publicat: (2021-03-01)

Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies
per: Elisabeth Maillart, et al.
Publicat: (2020-04-01)

Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
per: Piccolo, L, et al.
Publicat: (2016)

Corrigendum: Different immunological mechanisms between AQP4 antibody-positive and MOG antibody-positive optic neuritis based on RNA sequencing analysis of whole blood
per: Xuelian Chen, et al.
Publicat: (2023-08-01)

AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD
per: Prain, K, et al.
Publicat: (2019)

Frequency of Aqp4-Ab in patients with neuromyelitis optica (Devic's syndrome) is higher than predicted by NMO-IgG testing
per: Jarius, S, et al.
Publicat: (2007)

Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders.
per: Sato, D, et al.
Publicat: (2013)

MOG-IgG1 antibodies in children
per: Waters, P, et al.
Publicat: (2018)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
per: Kitley, J, et al.
Publicat: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
per: Kitley, J, et al.
Publicat: (2013)